Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
about
A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcomaAdaptive designs for dual-agent phase I dose-escalation studies.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Optimal modeling for phase I d ...... atin with 9-nitrocamptothecin.
@ast
Optimal modeling for phase I d ...... atin with 9-nitrocamptothecin.
@en
type
label
Optimal modeling for phase I d ...... atin with 9-nitrocamptothecin.
@ast
Optimal modeling for phase I d ...... atin with 9-nitrocamptothecin.
@en
prefLabel
Optimal modeling for phase I d ...... atin with 9-nitrocamptothecin.
@ast
Optimal modeling for phase I d ...... atin with 9-nitrocamptothecin.
@en
P2093
P1476
Optimal modeling for phase I d ...... latin with 9-nitrocamptothecin
@en
P2093
A P Kudelka
A Thalasila
Jong Ming Li
Zheming Gu
P2888
P304
P356
10.1007/S10637-008-9147-Y
P577
2008-07-04T00:00:00Z
P6179
1029180679